Intra-Cellular Therapies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Intra-Cellular Therapies yıllık ortalama 5.8% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 12.9% annual. Gelirler yılda ortalama 63.9% oranında büyüyor .

Anahtar bilgiler

5.8%

Kazanç büyüme oranı

15.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	7.3%
Gelir büyüme oranı	63.9%
Özkaynak getirisi	-7.5%
Net Marj	-14.1%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Intra-Cellular Therapies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:23I Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	614	-86	471
30 Jun 24	565	-84	445
31 Mar 24	514	-111	424
31 Dec 23	464	-140	410
30 Sep 23	420	-155	400
30 Jun 23	366	-184	383
31 Mar 23	311	-228	382
31 Dec 22	250	-256	359
30 Sep 22	188	-298	344
30 Jun 22	138	-321	326
31 Mar 22	103	-304	295
31 Dec 21	84	-284	273
30 Sep 21	71	-259	251
30 Jun 21	56	-237	233
31 Mar 21	38	-232	205
31 Dec 20	23	-227	186
30 Sep 20	10	-207	151
30 Jun 20	3	-187	113
31 Mar 20	1	-160	87
31 Dec 19	0	-148	65
30 Sep 19	0	-148	51
30 Jun 19	0	-155	44
31 Mar 19	0	-154	35
31 Dec 18	0	-155	30
30 Sep 18	0	-145	27
30 Jun 18	0	-126	24
31 Mar 18	0	-106	24
31 Dec 17	0	-98	24
30 Sep 17	0	-95	25
30 Jun 17	0	-102	26
31 Mar 17	0	-116	26
31 Dec 16	0	-116	25
30 Sep 16	0	-118	24
30 Jun 16	0	-120	22
31 Mar 16	0	-110	19
31 Dec 15	0	-105	18
30 Sep 15	0	-91	15
30 Jun 15	0	-65	14
31 Mar 15	0	-48	12
31 Dec 14	1	-31	10
30 Sep 14	1	-24	9
30 Jun 14	2	-22	8
31 Mar 14	2	-26	7
31 Dec 13	3	-27	6

Kaliteli Kazançlar: 23I şu anda kârlı değil.

Büyüyen Kar Marjı: 23I şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 23I kârlı değildir, ancak son 5 yılda zararlarını yılda 5.8% oranında azaltmıştır.

Büyüme Hızlandırma: 23I 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 23I kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 28.7% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 23I hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -7.54% ) sahiptir.

Intra-Cellular Therapies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.46 loss in 1Q 2023)

Full year 2023 earnings released: US$1.46 loss per share (vs US$2.73 loss in FY 2022)

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.45 loss per share (vs US$0.92 loss in 2Q 2022)

Recent updates

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

Intra-Cellular Therapies, Inc. Raises Financial Guidance for the Full Year 2024

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023)

Intra-Cellular Therapies, Inc. Raises Sales Guidance for 2024

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 2000 Dynamic Index

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.46 loss in 1Q 2023)

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 14, 2024

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

New minor risk - Shareholder dilution

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer

Full year 2023 earnings released: US$1.46 loss per share (vs US$2.73 loss in FY 2022)

New minor risk - Shareholder dilution

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024

Forecast to breakeven in 2025

EVP & Chief Commercial Officer recently sold €801k worth of stock

Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2022)

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.45 loss per share (vs US$0.92 loss in 2Q 2022)

Forecast to breakeven in 2025

Intra-Cellular Therapies, Inc. Announces CAPLYTA Data Presentations At the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.78 loss in 1Q 2022)

Full year 2022 earnings released: US$2.73 loss per share (vs US$3.50 loss in FY 2021)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Director recently sold €240k worth of stock

Independent Director recently sold €523k worth of stock

Independent Director recently sold €523k worth of stock

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$0.94 loss in 3Q 2021)

Independent Director recently sold €573k worth of stock

Second quarter 2022 earnings released: US$0.92 loss per share (vs US$0.85 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.65 loss in 1Q 2021)

Intra-Cellular Therapies, Inc. Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 09, 2022

Independent Director recently sold €736k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2024

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$0.79 loss in 3Q 2020)

Intra-Cellular Therapies, Inc. Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

Second quarter 2021 earnings released: US$0.85 loss per share (vs US$0.96 loss in 2Q 2020)

Forecast to breakeven in 2023

High number of new directors

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 1Q 2020)

Intra-Cellular Therapies Announces FDA Acceptance of Caplyta (Lumateperone) SNDAs for the Treatment of Bipolar Depression

Revenue beats expectations

Intra-Cellular Therapies Announces Expansion of Pipeline with the Introduction of New Molecular Entity, ITI-1284

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression

New 90-day high: €32.85

New 90-day high: €29.02

Intra-Cellular Therapies, Inc. Announces the Publication of Results from the CAPLYTA Clinical Trial (ITI-007-303)

New 90-day high: €27.41

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

New 90-day high: €23.82

Senior VP of Finance recently sold €174k worth of stock

Revenue beats expectations

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $350.00001 million.

New 90-day low - €15.16

New 90-day low - €16.08

First half earnings released